Pargyline (hydrochloride)

Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with Kis of 13 μM and 0.5 μM for MAO-A and MAO-B, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities[1][2][3]. Pargyline (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[306-07-0]

UNSPSC

12352005

Hazard Statement

H301

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Pargyline-hydrochloride.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

C#CCN(C)CC1=CC=CC=C1.[H]Cl

Molecular Formula

C11H14ClN

Molecular Weight

195.69

Precautions

H301

References & Citations

[1]C J Fowler, et al. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982 Nov 15;31 (22) :3555-61.|[2]Fuentes JA, et al. Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57 (1) :21-7.|[3]Hyung Tae Lee, et al. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep. 2013 Oct;30 (4) :1587-92.